Crossmark

Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN)

Crossref DOI link: https://doi.org/10.1007/s00432-019-03101-z

Published Online: 2019-12-02

Published Print: 2020-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Brioli, Annamaria https://orcid.org/0000-0002-4072-7592
Manz, Kirsi

Pfirrmann, Markus

Hänel, Mathias

Schwarzer, Andreas Christoph

Prange-Krex, Gabriele

Fabisch, Christian

Knop, Stefan

Illmer, Thomas

Krammer-Steiner, Beate

Hochhaus, Andreas

von Lilienfeld-Toal, Marie

Mügge, Lars-Olof
Funding

Funding for this research was provided by:

Celgene (RV-MM-PI-0745)
License Information

Text and Data Mining valid from 2019-12-02

Version of Record valid from 2019-12-02
More Information

Article History

Received: 24 October 2019

Accepted: 26 November 2019

First Online: 2 December 2019

Compliance with ethical standards

:

: AB received honoraria and travel support from Celgene, Takeda, Gilead and Janssen, honoraria from Sanofi and research support from Celgene; KM has no conflicts of interests to report; MP has no conflicts of interests to report; LOM received honoraria and travel support from Bristol-Myers Squibb, Celgene, Janssen, Novartis, Takeda and research support from Celgene; the other authors have no conflict of interest to report.

Document is current

Any future updates will be listed below